| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
■Focused Execution Drove 32% Operational Revenue Growth of Launched and Acquired Products(1) |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
■Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) |
| 18 Jun 2026 |
8-K: Regulation FD Disclosure
Following the disclosure of Pfizer’s Chief Financial Officer transition announcement on June 18, 2026, Pfizer today is reaffirming its fiscal year 2026 guidance introduced December 16, 2025 and reaffirmed on its first quarter earnings ca... |
| 18 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
NEW YORK, June 18, 2026—Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutic... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
■Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1) |
| 27 Apr 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 03 Feb 2026 |
8-K: Results of Operations and Financial Condition
■Focused Execution Drives Strong Full-Year 2025 EPS Performance |
| 16 Dec 2025 |
8-K: Regulation FD Disclosure
NEW YORK, December 16, 2025 — Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial gu... |
| 21 Nov 2025 |
8-K: Other Events
SIXTH SUPPLEMENTAL INDENTURE, dated as of November 21, 2025 (the “Sixth Supplemental Indenture”), between Pfizer Inc., a Delaware corporation (the “Company”), and The Bank of New York Mellon, a New York banking corporation, as trustee (t... |
| 13 Nov 2025 |
8-K: Other Events
On November 13, 2025, Pfizer Inc. (“Pfizer” or the “Company”) completed the previously announced acquisition of Metsera, Inc., a Delaware corporation (“Metsera”), pursuant to the Agreement and Plan of Merger, dated as of September 21, 20... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
■Landmark Agreement Reached with U.S. Government Provides Longer-Term Business Clarity |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
■Expanded Programs On Track to Deliver Net Cost Savings Targets |
| 19 May 2025 |
8-K: Other Events
This reconciliation and tie shall not, for any purpose, be deemed to be a part of the Indenture. |
| 29 Apr 2025 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities
■Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment |
| 28 Apr 2025 | 8-K: Submission of Matters to a Vote of Security Holders |
| 04 Feb 2025 |
8-K: Results of Operations and Financial Condition
–Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 12% Operationally |
| 17 Dec 2024 |
8-K: Regulation FD Disclosure
NEW YORK, December 17, 2024 — Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance(1) and reaffirmed its October 29, 2024 full-year 2024 guidance(1). The accompanying presentation can be found at www.pfizer.com/investors. |
| 29 Oct 2024 |
8-K: Results of Operations and Financial Condition
–Excluding Contributions from Paxlovid and Comirnaty(3), Revenues Grew 14% Operationally |
| 15 Oct 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
NEW YORK, October 15, 2024 – Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. B... |
Loading...